{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:21:59Z","timestamp":1791411719690,"version":"4.3.3"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Tirzepatide (TRZ) is a dual agonist of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors that were recently approved for the treatment of type 2 diabetes (T2D) and obesity. Of note is that T2D and obesity, by inducing peripheral low-grade inflammation and oxidative stress, provoke the development of central neuroinflammation and oxidative stress. Together, T2D and obesity are regarded as potential risk factors implicated in the development and progression of Alzheimer\u2019s disease (AD), which is the most common neurodegenerative disease and represents the most typical cause of dementia. Hence, targeting low-grade inflammation and oxidative stress in T2D and obesity by TRZ may reduce AD neuropathology. In addition, TRZ can inhibit the production of amyloid beta (A\u03b2) and associated neuroinflammation, oxidative stress, and neuronal apoptosis. However, the underlying neuroprotective mechanism of TRZ against AD is not entirely explained. Consequently, this mini-review aims to discuss the possible molecular mechanism of TRZ in AD.<\/jats:p>","DOI":"10.1007\/s11011-025-01649-z","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T10:09:41Z","timestamp":1749636581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tirzepatide: a novel therapeutic approach for Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"40","author":[{"given":"Ghadah H.","family":"Alshehri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda Jaber","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa A.","family":"Faheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-7236","authenticated-orcid":false,"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber","family":"El-Saber Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"1649_CR1","doi-asserted-by":"crossref","unstructured":"Al-Kuraishy HM et al. (2023a) The link between metabolic syndrome and Alzheimer disease: a mutual relationship and long rigorous investigation. Ageing Res Rev 91:102084","DOI":"10.1016\/j.arr.2023.102084"},{"issue":"1","key":"1649_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10787-022-01099-4","volume":"31","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM et al (2023b) Benzodiazepines in Alzheimer\u2019s disease: beneficial or detrimental effects. Inflammopharmacology 31(1):221\u2013230","journal-title":"Inflammopharmacology"},{"issue":"3","key":"1649_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11064-022-03817-4","volume":"48","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM et al (2023c) A potential link between visceral obesity and risk of Alzheimer\u2019s disease. Neurochem Res 48(3):745\u2013766","journal-title":"Neurochem Res"},{"issue":"3","key":"1649_CR4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10787-023-01163-7","volume":"31","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM et al (2023d) Long-term use of metformin and Alzheimer\u2019s disease: beneficial or detrimental effects. Inflammopharmacology 31(3):1107\u20131115","journal-title":"Inflammopharmacology"},{"key":"1649_CR5","doi-asserted-by":"publisher","first-page":"121532","DOI":"10.1016\/j.lfs.2023.121532","volume":"320","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM et al (2023e) Insights on benzodiazepines\u2019 potential in Alzheimer\u2019s disease. Life Sci 320:121532","journal-title":"Life Sci"},{"key":"1649_CR6","doi-asserted-by":"crossref","unstructured":"Al-Kuraishy HM et al (2023f) Evaluation and targeting of amyloid precursor protein (APP)\/amyloid beta (A\u03b2) axis in amyloidogenic and non-amyloidogenic pathways: a time outside the tunnel. Ageing Res Rev 92:102119","DOI":"10.1016\/j.arr.2023.102119"},{"key":"1649_CR7","doi-asserted-by":"crossref","unstructured":"Al-Kuraishy HM et al (2024a) Role of ketogenic diet in neurodegenerative diseases focusing on Alzheimer diseases: the guardian angle. Ageing Res Rev 95:102233","DOI":"10.1016\/j.arr.2024.102233"},{"key":"1649_CR8","doi-asserted-by":"crossref","unstructured":"Al-Kuraishy HM et al (2024b) New insight on the possible role of statins in Vascular Parkinsonism: a need for presumptive therapy. Ageing Res Rev 95:102209","DOI":"10.1016\/j.arr.2024.102209"},{"issue":"2","key":"1649_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000447447","volume":"6","author":"C Albala","year":"2016","unstructured":"Albala C et al (2016) Low leptin availability as a risk factor for dementia in Chilean older people. Dement Geriatric Cogn Disorders Extra 6(2):295\u2013302","journal-title":"Dement Geriatric Cogn Disorders Extra"},{"issue":"2","key":"1649_CR10","doi-asserted-by":"publisher","first-page":"e17993","DOI":"10.1111\/jcmm.17993","volume":"28","author":"NH Ali","year":"2024","unstructured":"Ali NH et al (2024a) Neprilysin inhibitors and risk of Alzheimer\u2019s disease: a future perspective. J Cell Mol Med 28(2):e17993","journal-title":"J Cell Mol Med"},{"issue":"23","key":"1649_CR11","doi-asserted-by":"publisher","first-page":"e70118","DOI":"10.1111\/jcmm.70118","volume":"28","author":"NH Ali","year":"2024","unstructured":"Ali NH et al (2024b) New insight on the potential detrimental effect of metabolic syndrome on the Alzheimer disease neuropathology: mechanistic role. J Cell Mol Med 28(23):e70118","journal-title":"J Cell Mol Med"},{"key":"1649_CR12","doi-asserted-by":"crossref","unstructured":"Alrouji M et al (2023) The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer\u2019s diseases. Diabetol Metab Syndr 15(1):101","DOI":"10.1186\/s13098-023-01082-1"},{"issue":"3","key":"1649_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/npr2.12445","volume":"44","author":"M Alrouji","year":"2024","unstructured":"Alrouji M et al (2024) Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: a new perspective. Neuropsychopharmacol Rep 44(3):639\u2013649","journal-title":"Neuropsychopharmacol Rep"},{"issue":"10","key":"1649_CR14","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3390\/brainsci12101290","volume":"12","author":"N Alsubaie","year":"2022","unstructured":"Alsubaie N et al (2022) Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci 12(10):1290","journal-title":"Brain Sci"},{"issue":"1","key":"1649_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/alz.12192","volume":"17","author":"AF Arnsten","year":"2021","unstructured":"Arnsten AF et al (2021) Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer\u2019s disease. Alzheimer\u2019s Dement 17(1):115\u2013124","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"1649_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ et al (2024) Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 331(1):38\u201348","journal-title":"JAMA"},{"key":"1649_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-020-01090-y","volume":"21","author":"T Ayodele","year":"2021","unstructured":"Ayodele T et al (2021) Early-onset Alzheimer\u2019s disease: what is missing in research? Curr Neurol Neurosci Rep 21:1\u201310","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1649_CR18","doi-asserted-by":"crossref","unstructured":"Baggio LL, Drucker DJ (2021) Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab 46:101090","DOI":"10.1016\/j.molmet.2020.101090"},{"key":"1649_CR19","doi-asserted-by":"publisher","first-page":"170202","DOI":"10.1016\/j.peptides.2019.170202","volume":"125","author":"CJ Bailey","year":"2020","unstructured":"Bailey CJ (2020) GIP analogues and the treatment of obesity-diabetes. Peptides 125:170202","journal-title":"Peptides"},{"key":"1649_CR20","doi-asserted-by":"publisher","first-page":"1281338","DOI":"10.3389\/fnagi.2023.1281338","volume":"15","author":"H Barmaki","year":"2023","unstructured":"Barmaki H, Nourazarian A, Khaki-Khatibi F (2023) Proteostasis and neurodegeneration: a closer look at autophagy in Alzheimer\u2019s disease. Front Aging Neurosci 15:1281338","journal-title":"Front Aging Neurosci"},{"key":"1649_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.freeradbiomed.2021.09.006","volume":"176","author":"E Barone","year":"2021","unstructured":"Barone E et al (2021) The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radic Biol Med 176:16\u201333","journal-title":"Free Radic Biol Med"},{"issue":"12","key":"1649_CR22","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.neurobiolaging.2007.04.024","volume":"29","author":"KA Baskerville","year":"2008","unstructured":"Baskerville KA et al (2008) Aging elevates metabolic gene expression in brain cholinergic neurons. Neurobiol Aging 29(12):1874\u20131893","journal-title":"Neurobiol Aging"},{"key":"1649_CR23","unstructured":"Bayhaghi G (2024) Assessing obesity-related risk factors in a heterogeneous adult population in the Southeast of the United States: a genetic and food intake behavioral study. Augusta University"},{"issue":"12","key":"1649_CR24","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1096\/fj.09-133454","volume":"23","author":"DD Belsham","year":"2009","unstructured":"Belsham DD et al (2009) Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. Faseb J 23(12):4256\u20134265","journal-title":"Faseb J"},{"key":"1649_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00125-018-4810-0","volume":"62","author":"NC Bergmann","year":"2019","unstructured":"Bergmann NC et al (2019) Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight\/obese individuals: a randomised, crossover study. Diabetologia 62:665\u2013675","journal-title":"Diabetologia"},{"issue":"3","key":"1649_CR26","doi-asserted-by":"publisher","first-page":"588","DOI":"10.2337\/dc19-0578","volume":"43","author":"NC Bergmann","year":"2020","unstructured":"Bergmann NC et al (2020) No acute effects of exogenous glucose-dependent insulinotropic polypeptide on energy intake, appetite, or energy expenditure when added to treatment with a long-acting glucagon-like peptide 1 receptor agonist in men with type 2 diabetes. Diabetes Care 43(3):588\u2013596","journal-title":"Diabetes Care"},{"issue":"1","key":"1649_CR27","doi-asserted-by":"publisher","first-page":"e3000585","DOI":"10.1371\/journal.pbio.3000585","volume":"18","author":"P Bhattarai","year":"2020","unstructured":"Bhattarai P et al (2020) Neuron-glia interaction through Serotonin-BDNF-NGFR axis enables regenerative neurogenesis in Alzheimer\u2019s model of adult zebrafish brain. PLoS Biol 18(1):e3000585","journal-title":"PLoS Biol"},{"issue":"1","key":"1649_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tips.2022.11.001","volume":"44","author":"GA Boer","year":"2023","unstructured":"Boer GA, Hay DL, Tups A (2023) Obesity pharmacotherapy: incretin action in the central nervous system. Trends Pharmacol Sci 44(1):50\u201363","journal-title":"Trends Pharmacol Sci"},{"key":"1649_CR29","doi-asserted-by":"crossref","unstructured":"Boutari C, DeMarsilis A, Mantzoros CS (2023) Obesity and diabetes. Diabetes Research and Clinical Practice 110773","DOI":"10.1016\/j.diabres.2023.110773"},{"issue":"3","key":"1649_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","volume":"20","author":"DA Butterfield","year":"2019","unstructured":"Butterfield DA, Halliwell B (2019) Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci 20(3):148\u2013160","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"1649_CR31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3233\/JAD-210256","volume":"83","author":"H-Y Cai","year":"2021","unstructured":"Cai H-Y et al (2021) A GLP-1\/GIP dual receptor agonist DA4-JC effectively attenuates cognitive impairment and pathology in the APP\/PS1\/Tau model of Alzheimer\u2019s disease 1. J Alzheimers Dis 83(2):799\u2013818","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1649_CR32","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12020-024-03757-9","volume":"84","author":"I Caruso","year":"2024","unstructured":"Caruso I, Giorgino F (2024) Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future. Endocrine 84(3):822\u2013835","journal-title":"Endocrine"},{"issue":"1","key":"1649_CR33","doi-asserted-by":"publisher","first-page":"10574","DOI":"10.1038\/s41598-018-28891-z","volume":"8","author":"T-J Chang","year":"2018","unstructured":"Chang T-J et al (2018) Genetic variation of SORBS1 gene is associated with glucose homeostasis and age at onset of diabetes: A SAPPHIRe cohort study. Sci Rep 8(1):10574","journal-title":"Sci Rep"},{"issue":"22","key":"1649_CR34","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.2174\/1389557522666220420094317","volume":"22","author":"N Chauhan","year":"2022","unstructured":"Chauhan N et al (2022) GSK-3\u03b2 and its inhibitors in Alzheimer\u2019s disease: a recent update. Mini Rev Med Chem 22(22):2881\u20132895","journal-title":"Mini Rev Med Chem"},{"issue":"13","key":"1649_CR35","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.3390\/molecules27134315","volume":"27","author":"VP Chavda","year":"2022","unstructured":"Chavda VP et al (2022) Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules 27(13):4315","journal-title":"Molecules"},{"issue":"6","key":"1649_CR36","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/molecules27061816","volume":"27","author":"Z-R Chen","year":"2022","unstructured":"Chen Z-R et al (2022) Role of cholinergic signaling in alzheimer\u2019s disease. Molecules 27(6):1816","journal-title":"Molecules"},{"issue":"4","key":"1649_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hipo.23504","volume":"33","author":"SH Choi","year":"2023","unstructured":"Choi SH, Tanzi RE (2023) Adult neurogenesis in Alzheimer\u2019s disease. Hippocampus 33(4):307\u2013321","journal-title":"Hippocampus"},{"issue":"1","key":"1649_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.17925\/EE.2023.19.1.16","volume":"19","author":"IM Colin","year":"2023","unstructured":"Colin IM et al (2023) Emerging evidence for the use of antidiabetic drugs, glucagon-like peptide 1 receptor agonists, for the treatment of Alzheimer\u2019s disease. TouchREVIEWS Endocrinol 19(1):16","journal-title":"TouchREVIEWS Endocrinol"},{"key":"1649_CR39","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1007\/s12035-016-0088-8","volume":"54","author":"M Cos\u00edn-Tom\u00e1s","year":"2017","unstructured":"Cos\u00edn-Tom\u00e1s M et al (2017) Plasma miR-34a-5p and miR-545-3p as early biomarkers of Alzheimer\u2019s disease: potential and limitations. Mol Neurobiol 54:5550\u20135562","journal-title":"Mol Neurobiol"},{"issue":"3","key":"1649_CR40","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/archneurol.2009.27","volume":"66","author":"S Craft","year":"2009","unstructured":"Craft S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66(3):300\u2013305","journal-title":"Arch Neurol"},{"issue":"1","key":"1649_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S et al (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69(1):29\u201338","journal-title":"Arch Neurol"},{"issue":"Suppl 1","key":"1649_CR42","first-page":"S263","volume":"33","author":"S Craft","year":"2013","unstructured":"Craft S, Cholerton B, Baker LD (2013) Insulin and Alzheimer\u2019s disease: untangling the web. J Alzheimers Dis 33(Suppl 1):S263\u2013S275","journal-title":"J Alzheimers Dis"},{"key":"1649_CR43","doi-asserted-by":"crossref","unstructured":"Craft S et al (2019) 1561-P: associations between \u00df-cell function and cognitive measures differ in youth vs. adults with impaired glucose tolerance (IGT) or early type 2 diabetes (T2D). Diabetes 68(Supplement_1)","DOI":"10.2337\/db19-1561-P"},{"issue":"4","key":"1649_CR44","doi-asserted-by":"publisher","first-page":"e21485","DOI":"10.1096\/fj.202002247RR","volume":"35","author":"Y Cui","year":"2021","unstructured":"Cui Y et al (2021) Melatonin prevents diabetes-associated cognitive dysfunction from microglia\u2010mediated neuroinflammation by activating autophagy via TLR4\/Akt\/mTOR pathway. FASEB J 35(4):e21485","journal-title":"FASEB J"},{"key":"1649_CR45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.freeradbiomed.2022.09.032","volume":"193","author":"S Dewanjee","year":"2022","unstructured":"Dewanjee S et al (2022) Altered glucose metabolism in Alzheimer\u2019s disease: role of mitochondrial dysfunction and oxidative stress. Free Radic Biol Med 193:134\u2013157","journal-title":"Free Radic Biol Med"},{"key":"1649_CR46","doi-asserted-by":"publisher","first-page":"1033479","DOI":"10.3389\/fendo.2022.1033479","volume":"13","author":"H Du","year":"2022","unstructured":"Du H et al (2022) The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease. Front Endocrinol 13:1033479","journal-title":"Front Endocrinol"},{"key":"1649_CR47","doi-asserted-by":"publisher","first-page":"e057848","DOI":"10.1002\/alz.057848","volume":"17","author":"P Edison","year":"2021","unstructured":"Edison P et al (2021) Evaluation of liraglutide in the treatment of Alzheimer\u2019s disease. Alzheimer\u2019s Dement 17:e057848","journal-title":"Alzheimer\u2019s Dement"},{"key":"1649_CR48","doi-asserted-by":"crossref","unstructured":"Finan B et al (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5(209):209ra151-209ra151","DOI":"10.1126\/scitranslmed.3007218"},{"issue":"9","key":"1649_CR49","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.3390\/ijms23095202","volume":"23","author":"JA Flores-Cordero","year":"2022","unstructured":"Flores-Cordero JA et al (2022) Obesity as a risk factor for dementia and Alzheimer\u2019s disease: the role of leptin. Int J Mol Sci 23(9):5202","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1649_CR50","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","volume":"22","author":"RA Fontanella","year":"2024","unstructured":"Fontanella RA et al (2024) Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Translational Med 22(1):114","journal-title":"J Translational Med"},{"key":"1649_CR51","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.molmet.2024.102019","volume":"89","author":"L Forny Germano","year":"2024","unstructured":"Forny Germano L et al (2024) The GLP-1 medicines semaglutide and Tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice. Mol Metab 89:102019","journal-title":"Mol Metab"},{"issue":"23","key":"1649_CR52","doi-asserted-by":"publisher","first-page":"14631","DOI":"10.3390\/ijms232314631","volume":"23","author":"I Forzano","year":"2022","unstructured":"Forzano I et al (2022) Tirzepatide: a systematic update. Int J Mol Sci 23(23):14631","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1649_CR53","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/01616412.2022.2056338","volume":"44","author":"S Fray","year":"2022","unstructured":"Fray S et al (2022) Association between H2 haplotype of microtubule associated protein Tau gene (deletion\/insertion) with Alzheimer disease in Tunisian patients. Neurol Res 44(9):814\u2013818","journal-title":"Neurol Res"},{"key":"1649_CR54","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fnins.2019.00629","volume":"13","author":"S Gabbouj","year":"2019","unstructured":"Gabbouj S et al (2019) Altered insulin signaling in Alzheimer\u2019s disease brain\u2013special emphasis on PI3K-Akt pathway. Front NeuroSci 13:629","journal-title":"Front NeuroSci"},{"key":"1649_CR55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.neuropharm.2018.01.008","volume":"136","author":"CM Griffith","year":"2018","unstructured":"Griffith CM et al (2018) Evidence for altered insulin receptor signaling in Alzheimer\u2019s disease. Neuropharmacology 136:202\u2013215","journal-title":"Neuropharmacology"},{"key":"1649_CR56","doi-asserted-by":"publisher","first-page":"1146960","DOI":"10.3389\/fphar.2023.1146960","volume":"14","author":"X Guo","year":"2023","unstructured":"Guo X et al (2023) Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats. Front Pharmacol 14:1146960","journal-title":"Front Pharmacol"},{"issue":"1","key":"1649_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1021\/acsami.1c15305","volume":"14","author":"S Gupta","year":"2021","unstructured":"Gupta S et al (2021) SiRNA mediated GSK3\u03b2 knockdown targets insulin signaling pathway and rescues Alzheimer\u2019s disease pathology: evidence from in vitro and in vivo studies. ACS Appl Mater Interfaces 14(1):69\u201393","journal-title":"ACS Appl Mater Interfaces"},{"issue":"3","key":"1649_CR58","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1042\/BJ20102148","volume":"440","author":"JA Handy","year":"2011","unstructured":"Handy JA et al (2011) Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J 440(3):385\u2013395","journal-title":"Biochem J"},{"key":"1649_CR59","doi-asserted-by":"publisher","first-page":"112308","DOI":"10.1016\/j.intimp.2024.112308","volume":"135","author":"NF Hassan","year":"2024","unstructured":"Hassan NF et al (2024) The potential role of Tirzepatide as adjuvant therapy in countering colistin-induced nephro and neurotoxicity in rats via modulation of PI3K\/p-Akt\/GSK3-\u03b2\/NF-kB p65 hub, shielding against oxidative and endoplasmic reticulum stress, and activation of p-CREB\/BDNF\/TrkB cascade. Int Immunopharmacol 135:112308","journal-title":"Int Immunopharmacol"},{"key":"1649_CR60","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3389\/fncel.2017.00266","volume":"11","author":"MR Holahan","year":"2017","unstructured":"Holahan MR (2017) A shift from a pivotal to supporting role for the growth-associated protein (GAP-43) in the coordination of axonal structural and functional plasticity. Front Cell Neurosci 11:266","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"1649_CR61","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4103\/1673-5374.354515","volume":"18","author":"C-W Huang","year":"2023","unstructured":"Huang C-W et al (2023) Altered O-GlcNAcylation and mitochondrial dysfunction, a molecular link between brain glucose dysregulation and sporadic Alzheimer\u2019s disease. Neural Regeneration Res 18(4):779\u2013783","journal-title":"Neural Regeneration Res"},{"key":"1649_CR62","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s00125-009-1422-8","volume":"52","author":"N Irwin","year":"2009","unstructured":"Irwin N, Flatt P (2009) Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 52:1724\u20131731","journal-title":"Diabetologia"},{"issue":"3","key":"1649_CR63","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387(3):205\u2013216","journal-title":"N Engl J Med"},{"key":"1649_CR64","doi-asserted-by":"crossref","unstructured":"Jensen TL et al (2024) The body weight reducing effects of Tirzepatide in people with and without type 2 diabetes: a review on efficacy and adverse effects. Patient preference and adherence 373\u2013382","DOI":"10.2147\/PPA.S419304"},{"issue":"1","key":"1649_CR65","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1515\/revneuro-2015-0021","volume":"27","author":"C Ji","year":"2016","unstructured":"Ji C et al (2016) Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer\u2019s disease. Rev Neurosci 27(1):61\u201370","journal-title":"Rev Neurosci"},{"issue":"2","key":"1649_CR66","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1567205010666131212114156","volume":"11","author":"M Johnston","year":"2014","unstructured":"Johnston M (2014) Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res 11(2):165\u2013174","journal-title":"Curr Alzheimer Res"},{"key":"1649_CR67","first-page":"101268","volume":"30","author":"D Kato","year":"2022","unstructured":"Kato D et al (2022) Comparative studies for amyloid beta degradation:neprilysin vs insulysin,monomeric vs aggregate, and whole A\u03b240 vs its peptide fragments. Biochem Biophys Rep 30:101268","journal-title":"Biochem Biophys Rep"},{"issue":"5","key":"1649_CR68","doi-asserted-by":"publisher","first-page":"6965","DOI":"10.1096\/fj.201902122RR","volume":"34","author":"Y Kim","year":"2020","unstructured":"Kim Y et al (2020) Microtubule-associated protein 2 mediates induction of long\u2010term potentiation in hippocampal neurons. FASEB J 34(5):6965\u20136983","journal-title":"FASEB J"},{"issue":"19","key":"1649_CR69","doi-asserted-by":"publisher","first-page":"10637","DOI":"10.3390\/ijms221910637","volume":"22","author":"J Kim","year":"2021","unstructured":"Kim J et al (2021) Donepezil regulates LPS and A\u03b2-stimulated neuroinflammation through MAPK\/NLRP3 inflammasome\/STAT3 signaling. Int J Mol Sci 22(19):10637","journal-title":"Int J Mol Sci"},{"issue":"14","key":"1649_CR70","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ajhp\/zxad080","volume":"80","author":"Z Krauss","year":"2023","unstructured":"Krauss Z, Hintz A, Fisk R (2023) Tirzepatide: clinical review of the twincretin injectable. Am J Health-System Pharm 80(14):879\u2013888","journal-title":"Am J Health-System Pharm"},{"issue":"1","key":"1649_CR71","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s12035-021-02611-7","volume":"59","author":"M Kumar","year":"2022","unstructured":"Kumar M, Bansal N (2022) Implications of phosphoinositide 3-kinase-Akt (PI3K-Akt) pathway in the pathogenesis of Alzheimer\u2019s disease. Mol Neurobiol 59(1):354\u2013385","journal-title":"Mol Neurobiol"},{"issue":"4","key":"1649_CR72","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3390\/nu14040745","volume":"14","author":"M-C Lai","year":"2022","unstructured":"Lai M-C et al (2022) The citrus flavonoid hesperetin encounters diabetes-mediated Alzheimer-type neuropathologic changes through relieving advanced glycation end-products inducing endoplasmic reticulum stress. Nutrients 14(4):745","journal-title":"Nutrients"},{"key":"1649_CR73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12031-010-9482-2","volume":"45","author":"A Lanzillotta","year":"2011","unstructured":"Lanzillotta A et al (2011) The \u03b3-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer\u2019s disease. J Mol Neurosci 45:22\u201331","journal-title":"J Mol Neurosci"},{"issue":"11","key":"1649_CR74","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.3390\/ijms22115603","volume":"22","author":"A Litwiniuk","year":"2021","unstructured":"Litwiniuk A et al (2021) Inflammasome NLRP3 potentially links obesity-associated low-grade systemic inflammation and insulin resistance with Alzheimer\u2019s disease. Int J Mol Sci 22(11):5603","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1649_CR75","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.imbio.2015.02.004","volume":"220","author":"Z Liu","year":"2015","unstructured":"Liu Z et al (2015) SOCS3 promotes inflammation and apoptosis via inhibiting JAK2\/STAT3 signaling pathway in 3T3-L1 adipocyte. Immunobiology 220(8):947\u2013953","journal-title":"Immunobiology"},{"key":"1649_CR76","doi-asserted-by":"publisher","first-page":"648636","DOI":"10.3389\/fphar.2021.648636","volume":"12","author":"H-Z Long","year":"2021","unstructured":"Long H-Z et al (2021) PI3K\/AKT signal pathway: a target of natural products in the prevention and treatment of Alzheimer\u2019s disease and parkinson\u2019s disease. Front Pharmacol 12:648636","journal-title":"Front Pharmacol"},{"issue":"2","key":"1649_CR77","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s12020-024-04013-w","volume":"87","author":"J Ma","year":"2025","unstructured":"Ma J et al (2025) Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis. Endocrine 87(2):486\u2013497","journal-title":"Endocrine"},{"issue":"1","key":"1649_CR78","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/acel.12281","volume":"14","author":"S Maioli","year":"2015","unstructured":"Maioli S et al (2015) Alterations in brain leptin signalling in spite of unchanged CSF leptin levels in Alzheimer\u2019s disease. Aging Cell 14(1):122\u2013129","journal-title":"Aging Cell"},{"key":"1649_CR79","doi-asserted-by":"publisher","first-page":"102575","DOI":"10.1016\/j.conb.2022.102575","volume":"75","author":"A Mangalmurti","year":"2022","unstructured":"Mangalmurti A, Lukens JR (2022) How neurons die in Alzheimer\u2019s disease: implications for neuroinflammation. Curr Opin Neurobiol 75:102575","journal-title":"Curr Opin Neurobiol"},{"key":"1649_CR80","doi-asserted-by":"publisher","first-page":"153331752095304","DOI":"10.1177\/1533317520953041","volume":"35","author":"M Maskery","year":"2020","unstructured":"Maskery M et al (2020) The dual GLP-1\/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP\/PS1 mouse model of Alzheimer\u2019s disease. Am J Alzheimer\u2019s Disease Other Dementias\u00ae 35:1533317520953041","journal-title":"Am J Alzheimer\u2019s Disease Other Dementias\u00ae"},{"key":"1649_CR81","doi-asserted-by":"publisher","first-page":"170749","DOI":"10.1016\/j.peptides.2022.170749","volume":"151","author":"A Mayendraraj","year":"2022","unstructured":"Mayendraraj A, Rosenkilde MM, Gasbjerg LS (2022) GLP-1 and GIP receptor signaling in beta cells\u2013a review of receptor interactions and co-stimulation. Peptides 151:170749","journal-title":"Peptides"},{"key":"1649_CR82","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.neuropharm.2017.09.038","volume":"136","author":"G McGregor","year":"2018","unstructured":"McGregor G, Harvey J (2018) Food for thought: leptin regulation of hippocampal function and its role in Alzheimer\u2019s disease. Neuropharmacology 136:298\u2013306","journal-title":"Neuropharmacology"},{"key":"1649_CR83","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10571-015-0282-7","volume":"36","author":"MJ McGuire","year":"2016","unstructured":"McGuire MJ, Ishii M (2016) Leptin dysfunction and Alzheimer\u2019s disease: evidence from cellular, animal, and human studies. Cell Mol Neurobiol 36:203\u2013217","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"1649_CR84","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","volume":"12","author":"T Min","year":"2021","unstructured":"Min T, Bain SC (2021) The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Therapy 12(1):143\u2013157","journal-title":"Diabetes Therapy"},{"key":"1649_CR85","volume-title":"Sex-Dependent molecular landscape of alzheimer\u2019s disease revealed by Large-Scale Single-Cell transcriptomics","author":"S Mohamed","year":"2024","unstructured":"Mohamed S, Le Bars S (2024) and E. GLAAB, Sex-Dependent molecular landscape of Alzheimer\u2019s disease revealed by large-scale single-cell transcriptomics. the Journal of the Alzheimer\u2019s Association, Alzheimer\u2019s and Dementia"},{"issue":"9","key":"1649_CR86","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/ijms21093165","volume":"21","author":"TT Nguyen","year":"2020","unstructured":"Nguyen TT et al (2020) Type 3 diabetes and its role implications in Alzheimer\u2019s disease. Int J Mol Sci 21(9):3165","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1649_CR87","first-page":"540","volume":"22","author":"W Nong","year":"2022","unstructured":"Nong W et al (2022) miR-212-3p attenuates neuroinflammation of rats with Alzheimer\u2019s disease via regulating the SP1\/BACE1\/NLRP3\/Caspase-1 signaling pathway. Bosnian J Basic Med Sci 22(4):540","journal-title":"Bosnian J Basic Med Sci"},{"issue":"1","key":"1649_CR88","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","volume":"28","author":"J Nowell","year":"2023","unstructured":"Nowell J, Blunt E, Edison P (2023) Incretin and insulin signaling as novel therapeutic targets for Alzheimer\u2019s and parkinson\u2019s disease. Mol Psychiatry 28(1):217\u2013229","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1649_CR89","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.metabol.2014.07.014","volume":"64","author":"G Paz-Filho","year":"2015","unstructured":"Paz-Filho G, Mastronardi CA, Licinio J (2015) Leptin treatment: facts and expectations. Metabolism 64(1):146\u2013156","journal-title":"Metabolism"},{"key":"1649_CR90","doi-asserted-by":"crossref","unstructured":"Perovic M et al (2024) The presymptomatic treatment with 3HFWC nanosubstance decreased plaque load in 5XFAD mouse model of Alzheimer\u2019s disease. CNS Neuroscie Ther 30(3):e14188","DOI":"10.1111\/cns.14188"},{"issue":"3","key":"1649_CR91","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.clinthera.2023.12.014","volume":"46","author":"J Powell","year":"2024","unstructured":"Powell J, Taylor J (2024) Use of dulaglutide, semaglutide, and Tirzepatide in diabetes and weight management. Clin Ther 46(3):289\u2013292","journal-title":"Clin Ther"},{"issue":"2","key":"1649_CR92","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.drudis.2018.11.005","volume":"24","author":"JA Pradeepkiran","year":"2019","unstructured":"Pradeepkiran JA, Reddy AP, Reddy PH (2019) Pharmacophore-based models for therapeutic drugs against phosphorylated Tau in Alzheimer\u2019s disease. Drug Discovery Today 24(2):616\u2013623","journal-title":"Drug Discovery Today"},{"key":"1649_CR93","doi-asserted-by":"crossref","unstructured":"Pugazhenthi S, Qin L, Reddy PH (2017) Common neurodegenerative pathways in obesity, diabetes, and Alzheimer\u2019s disease. Biochim Biophys Acta (BBA)-Mol Basis Dis. 1863(5):1037\u20131045","DOI":"10.1016\/j.bbadis.2016.04.017"},{"issue":"Supplement1","key":"1649_CR94","first-page":"bvae163","volume":"8","author":"SD Rao","year":"2024","unstructured":"Rao SD et al (2024) 8447 A short-term tirzepatide treatment improves insulin sensitivity and reduces Leptin-Ghrelin ratio in diet-induced obese mice. J Endocr Soc 8(Supplement1):bvae163","journal-title":"J Endocr Soc"},{"issue":"7","key":"1649_CR95","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/biomedicines10071582","volume":"10","author":"EM Rhea","year":"2022","unstructured":"Rhea EM, Banks WA, Raber J (2022) Insulin resistance in peripheral tissues and the brain: a tale of two sites. Biomedicines 10(7):1582","journal-title":"Biomedicines"},{"issue":"4","key":"1649_CR96","doi-asserted-by":"publisher","first-page":"2292461","DOI":"10.1080\/21688370.2023.2292461","volume":"12","author":"EM Rhea","year":"2024","unstructured":"Rhea EM et al (2024) Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases. Tissue Barriers 12(4):2292461","journal-title":"Tissue Barriers"},{"issue":"9","key":"1649_CR97","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","volume":"184","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez PJ et al (2024) Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med 184(9):1056\u20131064","journal-title":"JAMA Intern Med"},{"issue":"4","key":"1649_CR98","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.3390\/ijms24043384","volume":"24","author":"E Roh","year":"2023","unstructured":"Roh E, Choi KM (2023) Hormonal gut\u2013brain signaling for the treatment of obesity. Int J Mol Sci 24(4):3384","journal-title":"Int J Mol Sci"},{"key":"1649_CR99","doi-asserted-by":"crossref","unstructured":"Samms RJ et al (2021) GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest 131(12)","DOI":"10.1172\/JCI146353"},{"issue":"1","key":"1649_CR100","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12035-011-8229-6","volume":"46","author":"HB Schi\u00f6th","year":"2012","unstructured":"Schi\u00f6th HB et al (2012) Brain insulin signaling and Alzheimer\u2019s disease: current evidence and future directions. Mol Neurobiol 46(1):4\u201310","journal-title":"Mol Neurobiol"},{"key":"1649_CR101","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fendo.2014.00110","volume":"5","author":"I Sebasti\u00e3o","year":"2014","unstructured":"Sebasti\u00e3o I et al (2014) Insulin as a Bridge between type 2 diabetes and Alzheimer disease\u2013how anti-diabetics could be a solution for dementia. Front Endocrinol 5:110","journal-title":"Front Endocrinol"},{"issue":"14","key":"1649_CR102","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.2174\/1567205018666210218152253","volume":"17","author":"VK Sharma","year":"2020","unstructured":"Sharma VK, Singh TG (2020) CREB: a multifaceted target for Alzheimer\u2019s disease. Curr Alzheimer Res 17(14):1280\u20131293","journal-title":"Curr Alzheimer Res"},{"issue":"12","key":"1649_CR103","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/s43587-021-00146-z","volume":"1","author":"HS Shim","year":"2021","unstructured":"Shim HS et al (2021) Telomerase reverse transcriptase preserves neuron survival and cognition in Alzheimer\u2019s disease models. Nat Aging 1(12):1162\u20131174","journal-title":"Nat Aging"},{"issue":"4","key":"1649_CR104","doi-asserted-by":"publisher","first-page":"688","DOI":"10.34172\/apb.2023.071","volume":"13","author":"SR Shri","year":"2023","unstructured":"Shri SR et al (2023) Role of GSK-3\u03b2 inhibitors: new promises and opportunities for Alzheimer\u2019s disease. Adv Pharm Bull 13(4):688","journal-title":"Adv Pharm Bull"},{"key":"1649_CR105","doi-asserted-by":"crossref","unstructured":"Simental-Mend\u00eda LE et al (2024) Effect of Tirzepatide on leptin and adiponectin levels. Eur J Intern Med","DOI":"10.1016\/j.ejim.2024.07.037"},{"issue":"1","key":"1649_CR106","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12933-024-02203-4","volume":"23","author":"F Taktaz","year":"2024","unstructured":"Taktaz F et al (2024) Evidence that Tirzepatide protects against diabetes-related cardiac damages. Cardiovasc Diabetol 23(1):112","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1649_CR107","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/nmt.13.73","volume":"4","author":"K Talbot","year":"2014","unstructured":"Talbot K (2014) Brain insulin resistance in Alzheimer\u2019s disease and its potential treatment with GLP-1 analogs. Neurodegener Dis Manag 4(1):31\u201340","journal-title":"Neurodegener Dis Manag"},{"issue":"4","key":"1649_CR108","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K et al (2012) Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122(4):1316\u20131338","journal-title":"J Clin Invest"},{"issue":"8","key":"1649_CR109","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","volume":"47","author":"B Tan","year":"2023","unstructured":"Tan B et al (2023) Efficacy and safety of Tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes 47(8):677\u2013685","journal-title":"Int J Obes"},{"issue":"21","key":"1649_CR110","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.3390\/molecules29215131","volume":"29","author":"AM Thawabteh","year":"2024","unstructured":"Thawabteh AM et al (2024) Recent advances in therapeutics for the treatment of Alzheimer\u2019s disease. Molecules 29(21):5131","journal-title":"Molecules"},{"issue":"3","key":"1649_CR111","doi-asserted-by":"publisher","first-page":"E224","DOI":"10.1152\/ajpendo.00347.2016","volume":"312","author":"SK Thondam","year":"2017","unstructured":"Thondam SK et al (2017) Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. Am J Physiology-Endocrinology Metabolism 312(3):E224\u2013E233","journal-title":"Am J Physiology-Endocrinology Metabolism"},{"issue":"4","key":"1649_CR112","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/ijms21041413","volume":"21","author":"T Tomiyama","year":"2020","unstructured":"Tomiyama T, Shimada H (2020) APP Osaka mutation in familial Alzheimer\u2019s disease\u2014Its discovery, phenotypes, and mechanism of recessive inheritance. Int J Mol Sci 21(4):1413","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1649_CR113","first-page":"211","volume":"55","author":"M \u00dclker","year":"2018","unstructured":"\u00dclker M, Kenangil G (2018) The relation of circulating levels of leptin with cognition in patients with Alzheimer\u2019s disease. Archives Neuropsychiatry 55(3):211","journal-title":"Archives Neuropsychiatry"},{"key":"1649_CR114","doi-asserted-by":"crossref","unstructured":"Willard FS et al (2020) Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5(17)","DOI":"10.1172\/jci.insight.140532"},{"key":"1649_CR115","doi-asserted-by":"crossref","unstructured":"Wilson M et al (2014) Autophagy dysfunction and its link to Alzheimer\u2019s disease and type II diabetes mellitus. CNS Neurol Disord-Drug Targets (Formerly Current\u00a0Drug Targets-CNS & Neurological Disorders). 13(2):226\u2013246","DOI":"10.2174\/18715273113126660146"},{"key":"1649_CR116","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.neurobiolaging.2019.08.013","volume":"86","author":"I Wohlers","year":"2020","unstructured":"Wohlers I et al (2020) Alzheimer\u2019s disease risk SNPs show no strong effect on MiRNA expression in human lymphoblastoid cell lines. Neurobiol Aging 86:202e1-202. e3","journal-title":"Neurobiol Aging"},{"key":"1649_CR117","doi-asserted-by":"publisher","first-page":"113499","DOI":"10.1016\/j.intimp.2024.113499","volume":"143","author":"Y Xia","year":"2024","unstructured":"Xia Y et al (2024) Tirzepatide\u2019s role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance. Int Immunopharmacol 143:113499","journal-title":"Int Immunopharmacol"},{"key":"1649_CR118","doi-asserted-by":"publisher","first-page":"171271","DOI":"10.1016\/j.peptides.2024.171271","volume":"179","author":"S Yang","year":"2024","unstructured":"Yang S et al (2024a) Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP\/PS1 mice. Peptides 179:171271","journal-title":"Peptides"},{"key":"1649_CR119","doi-asserted-by":"publisher","first-page":"1453825","DOI":"10.3389\/fphar.2024.1453825","volume":"15","author":"J Yang","year":"2024","unstructured":"Yang J et al (2024b) Tirzepatide\u2019s innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health. Front Pharmacol 15:1453825","journal-title":"Front Pharmacol"},{"issue":"3","key":"1649_CR120","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.neuroimage.2010.03.040","volume":"51","author":"MA Yassa","year":"2010","unstructured":"Yassa MA et al (2010) High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic mild cognitive impairment. NeuroImage 51(3):1242\u20131252","journal-title":"NeuroImage"},{"issue":"5","key":"1649_CR121","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/00207454.2021.1924707","volume":"133","author":"L Zhang","year":"2023","unstructured":"Zhang L, Zhang W, Tian X (2023) The pleiotropic of GLP-1\/GLP-1R axis in central nervous system diseases. Int J Neurosci 133(5):473\u2013491","journal-title":"Int J Neurosci"},{"issue":"4","key":"1649_CR122","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13205-021-02738-3","volume":"11","author":"M Zheng","year":"2021","unstructured":"Zheng M, Wang P (2021) Role of insulin receptor substance-1 modulating PI3K\/Akt insulin signaling pathway in Alzheimer\u2019s disease. 3 Biotech 11(4):179","journal-title":"3 Biotech"},{"issue":"1","key":"1649_CR123","doi-asserted-by":"publisher","first-page":"26859","DOI":"10.1038\/srep26859","volume":"6","author":"H Zhu","year":"2016","unstructured":"Zhu H et al (2016) The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K\/AKT and MAPK pathways. Sci Rep 6(1):26859","journal-title":"Sci Rep"},{"key":"1649_CR124","doi-asserted-by":"publisher","first-page":"1422130","DOI":"10.3389\/fncel.2024.1422130","volume":"18","author":"I Zota","year":"2024","unstructured":"Zota I et al (2024) Stimulating Myelin restoration with BDNF: a promising therapeutic approach for Alzheimer\u2019s disease. Front Cell Neurosci 18:1422130","journal-title":"Front Cell Neurosci"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-025-01649-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-025-01649-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-025-01649-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T07:03:43Z","timestamp":1750921423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-025-01649-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":124,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["1649"],"URL":"https:\/\/doi.org\/10.1007\/s11011-025-01649-z","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial"}}],"article-number":"221"}}